Lead Product(s) : Belapectin
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The publication provides further clinical evidence that using belapectin, in combination with pembrolizumab significantly enhances tumor response to immunotherapy in patients with advanced metastatic melanoma (MM) and head and neck squamous cell carcino...
Product Name : GR-MD-02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2021
Lead Product(s) : Belapectin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable